182 related articles for article (PubMed ID: 35497510)
1. Dietary stigmastane-type saponins as promising dual-target directed inhibitors of SARS-CoV-2 proteases: a structure-based screening.
Ogunyemi OM; Gyebi GA; Ibrahim IM; Olaiya CO; Ocheje JO; Fabusiwa MM; Adebayo JO
RSC Adv; 2021 Oct; 11(53):33380-33398. PubMed ID: 35497510
[TBL] [Abstract][Full Text] [Related]
2. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
Abdizadeh R; Hadizadeh F; Abdizadeh T
Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
[TBL] [Abstract][Full Text] [Related]
3. Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum.
Gyebi GA; Elfiky AA; Ogunyemi OM; Ibrahim IM; Adegunloye AP; Adebayo JO; Olaiya CO; Ocheje JO; Fabusiwa MM
Comput Biol Med; 2021 Sep; 136():104671. PubMed ID: 34332348
[TBL] [Abstract][Full Text] [Related]
4. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.
Gogoi M; Borkotoky M; Borchetia S; Chowdhury P; Mahanta S; Barooah AK
J Biomol Struct Dyn; 2022 Sep; 40(15):7143-7166. PubMed ID: 33715595
[TBL] [Abstract][Full Text] [Related]
5. Screening of phytochemicals as potent inhibitor of 3-chymotrypsin and papain-like proteases of SARS-CoV2: an in silico approach to combat COVID-19.
Swargiary A; Mahmud S; Saleh MA
J Biomol Struct Dyn; 2022 Mar; 40(5):2067-2081. PubMed ID: 33089730
[TBL] [Abstract][Full Text] [Related]
6.
Rudrapal M; Issahaku AR; Agoni C; Bendale AR; Nagar A; Soliman MES; Lokwani D
J Biomol Struct Dyn; 2022; 40(20):10437-10453. PubMed ID: 34182889
[TBL] [Abstract][Full Text] [Related]
7. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
Báez-Santos YM; St John SE; Mesecar AD
Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations.
Tumskiy RS; Tumskaia AV; Klochkova IN; Richardson RJ
Comput Biol Med; 2023 Feb; 153():106449. PubMed ID: 36586228
[TBL] [Abstract][Full Text] [Related]
9. A multi-targeted approach to identify potential flavonoids against three targets in the SARS-CoV-2 life cycle.
Kumar S; Paul P; Yadav P; Kaul R; Maitra SS; Jha SK; Chaari A
Comput Biol Med; 2022 Mar; 142():105231. PubMed ID: 35032740
[TBL] [Abstract][Full Text] [Related]
10. In-silico docking studies of selected phytochemicals against papain like protease of SARS-Cov-2.
Saranya P; Karunya R; Keerthi Varshini G; Kowsikan K; Prathiksha R
Vegetos; 2023; 36(1):188-194. PubMed ID: 36530568
[TBL] [Abstract][Full Text] [Related]
11. Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches.
Bhowmick S; Saha A; AlFaris NA; ALTamimi JZ; ALOthman ZA; Aldayel TS; Wabaidur SM; Islam MA
J Mol Graph Model; 2022 Mar; 111():108113. PubMed ID: 34959151
[TBL] [Abstract][Full Text] [Related]
12. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
13. Strategic analyses to identify key structural features of antiviral/antimalarial compounds for their binding interactions with 3CLpro, PLpro and RdRp of SARS-CoV-2:
Dhote AM; Patil VR; Lokwani DK; Amnerkar ND; Ugale VG; Charbe NB; Bhongade BA; Khadse SC
J Biomol Struct Dyn; 2022; 40(22):11914-11931. PubMed ID: 34431452
[TBL] [Abstract][Full Text] [Related]
14. Identification of natural compounds (proanthocyanidin and rhapontin) as high-affinity inhibitors of SARS-CoV-2 Mpro and PLpro using computational strategies.
AlAjmi MF; Azhar A; Hasan S; Alshabr AZ; Hussain A; Rehman MT
Arch Med Sci; 2024; 20(2):567-581. PubMed ID: 38757037
[TBL] [Abstract][Full Text] [Related]
15.
Srivastava R; Panda SK; Sen Gupta PS; Chaudhary A; Naaz F; Yadav AK; Ram NK; Rana MK; Singh RK; Srivastava R
J Biomol Struct Dyn; 2023 Dec; ():1-18. PubMed ID: 38147408
[TBL] [Abstract][Full Text] [Related]
16. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
[TBL] [Abstract][Full Text] [Related]
17. Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources.
Razali R; Asis H; Budiman C
Microorganisms; 2021 Nov; 9(12):. PubMed ID: 34946083
[TBL] [Abstract][Full Text] [Related]
18. Promising antivirals for PLpro of SARS-CoV-2 using virtual screening, molecular docking, dynamics, and MMPBSA.
Kumari R; Kumar V; Dhankhar P; Dalal V
J Biomol Struct Dyn; 2023 Jul; 41(10):4650-4666. PubMed ID: 35510600
[TBL] [Abstract][Full Text] [Related]
19. Repurposing of phytomedicine-derived bioactive compounds with promising anti-SARS-CoV-2 potential: Molecular docking, MD simulation and drug-likeness/ADMET studies.
Rudrapal M; Gogoi N; Chetia D; Khan J; Banwas S; Alshehri B; Alaidarous MA; Laddha UD; Khairnar SJ; Walode SG
Saudi J Biol Sci; 2022 Apr; 29(4):2432-2446. PubMed ID: 34924801
[TBL] [Abstract][Full Text] [Related]
20. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.
Gupta Y; Maciorowski D; Zak SE; Jones KA; Kathayat RS; Azizi SA; Mathur R; Pearce CM; Ilc DJ; Husein H; Herbert AS; Bharti A; Rathi B; Durvasula R; Becker DP; Dickinson BC; Dye JM; Kempaiah P
Methods; 2021 Nov; 195():57-71. PubMed ID: 33453392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
